Samuel Isaly’s OrbiMed Advisors manages around $5 Billion in healthcare related equities and venture capital. Eaton Vance Worldwide Health Sciences Fund managed to beat the S&P 500 index by more than 5 percentage points per year since Isaly took over in 1989. Isaly has economics degrees from Princeton and the London School of Economics.
This week OrbiMed started selling nearly 130 thousand shares of Anthera Pharmaceuticals (ANTH). They received around $7.23 per share on the average. OrbiMed still has more than 3.3 Million shares of Anthera. ANTH was trading below $4 at the beginning of February. The 75+% return might have induced some profit taking. Anthera’s large shareholder Vantagepoint Venture Associates sold nearly 700 thousand shares earlier this month. Jacob Gottlieb’s Visium Asset Management also had 1.6 Million shares of ANTH in its portfolio at the end of December.
According to Yahoo Finance Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat diseases associated with inflammation, including cardiovascular and autoimmune diseases. Its primary product candidates include varespladib methyl (A-002), which has completed its Phase 2 clinical studies for the treatment of acute coronary syndrome; varespladib sodium (A-001) that is in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease; and A-623, which has completed Phase 1 clinical studies for the treatment of B-cell mediated autoimmune diseases. The company has license agreements with Eli Lilly and Company, and Shionogi & Co., Ltd. to develop and commercialize secretory phospholipase A2 or sPLA2 inhibitors for the treatment of cardiovascular disease and other diseases; and Amgen Inc., to develop and commercialize A-623. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.